Evidence map›Paper›PMID 38826449›Full record

ArticlebioRxiv : the preprint server for biology2024

FDA-Approved MEK1/2 Inhibitor, Trametinib, Protects Mice from Cisplatin and Noise-Induced Hearing Loss.

Richard D Lutze, Matthew A Ingersoll, Regina G Kelmann, Tal Teitz

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Richard D LutzeDepartment of Pharmacology and Neuroscience, School of Medicine, Creighton University, Omaha, NE 68178, USA.
Matthew A IngersollDepartment of Pharmacology and Neuroscience, School of Medicine, Creighton University, Omaha, NE 68178, USA.
Regina G KelmannDepartment of Pharmacology and Neuroscience, School of Medicine, Creighton University, Omaha, NE 68178, USA.
Tal TeitzDepartment of Pharmacology and Neuroscience, School of Medicine, Creighton University, Omaha, NE 68178, USA.

Funding

UNMC Structural Biology CoreP20GM103427 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PAUL L SORGEN · 2012 to 2026
$59.2M
ZINC FINGER-INSPIRED FLUORESCENT CHEMOSENSORSP20RR016469 · NCRR · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI TURPEN, JAMES B · 2001 to 2011
$36.2M
Understanding the progression of hearing loss in an endolymphatic hydrops modelP20GM139762 · NIGMS · CREIGHTON UNIVERSITY · PI Peter Stephen Steyger · 2021 to 2026
$16.1M
Repurposing an FDA approved Drug, B-Raf Kinase Inhibitor Dabrafenib for Protection from Cisplatin- and Noise- induced Hearing LossR01DC018850 · NIDCD · SCINTILLON INSTITUTE FOR PHOTOBIOLOGY · PI TEITZ, TAL · 2021 to 2025
$2.3M
Replacing an Animal Resource Facility Cage Washer.G20RR024001 · NCRR · CREIGHTON UNIVERSITY · PI DRESCHER, KRISTEN · 2007 to 2007
$638k
Repurposing FDA-Approved MEK Inhibitor Trametinib for Protection Against Cisplatin-Induced Hearing LossF32DC020102 · NIDCD · CREIGHTON UNIVERSITY · PI INGERSOLL, MATTHEW A · 2021 to 2023
$121k
NCRR NIH HHS G20 RR024001NCRR NIH HHS P20 RR016469NIDCD NIH HHS F32 DC020102NIDCD NIH HHS R01 DC018850NIGMS NIH HHS P20 GM103427NIGMS NIH HHS P20 GM139762
6 · The paper itself

Abstract

Hearing loss is one of the most common types of disability; however, there is only one FDA-approved drug to prevent any type of hearing loss. Treatment with the highly effective chemotherapy agent, cisplatin, and exposure to high decibel noises are two of the most common causes of hearing loss. The mitogen activated protein kinase (MAPK) pathway, a phosphorylation cascade consisting of RAF, MEK1/2, and ERK1/2, has been implicated in both types of hearing loss. Pharmacologically inhibiting BRAF or ERK1/2 is protective from noise and cisplatin-induced hearing loss in multiple mouse models. Trametinib, a MEK1/2 inhibitor, protects from cisplatin induced outer hair cell death in mouse cochlear explants; however, to the best of our knowledge, inhibiting MEK1/2 has not yet been shown to be protective from hearing loss

Indexed as

cisplatin-induced hearing lossdrug repurposing, oral deliveryhearing protectionMAPK pathwayMEK1/2noise-induced hearing losstrametinib

Identifiers

PMID38826449
PMCPMC11142120

What Socratic holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.